Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule

N Suzuki1, K Del Villar, F Tamanoi

  • 1Department of Microbiology and Molecular Genetics, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 405 Hilgard Avenue, Los Angeles, CA 90095-1489, USA.

Insights

Farnesyltransferase inhibitors (FTIs) reverse cancer cell morphology by impacting microtubule networks, not actin. This suggests FTIs

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Farnesyltransferase inhibitors (FTIs) are known to inhibit cancer cell phenotypes and growth.
  • Ras-transformed cells often exhibit altered morphology and cytoskeletal organization.

Purpose of the Study:

  • To investigate the morphological effects of FTIs on v-K-ras-transformed NRK cells (KNRK).
  • To elucidate the role of cytoskeletal dynamics, specifically actin and microtubules, in FTI-induced morphological changes.

Main Methods:

  • Treatment of KNRK and untransformed NRK cells with FTIs.
  • Phalloidin staining to assess actin cytoskeleton.
  • Microscopy to observe cell morphology.
  • Treatment with microtubule-targeting agents (vincristine, vinblastine) and actin-polymerization inhibitors (cytochalasin B).
  • Cell cycle analysis using flow cytometry.

Main Results:

  • FTI treatment induced significant morphological changes in KNRK cells, reverting them to an untransformed-like appearance.
  • FTIs did not restore the disrupted actin cytoskeleton but promoted extensive microtubule networks.
  • Microtubule-targeting agents blocked FTI-induced morphological changes, while cytochalasin B did not.
  • FTI treatment decreased the percentage of cells in S-phase, and higher vincristine concentrations synergized with FTIs to arrest cells in G2/M phase.

Conclusions:

  • FTIs induce dramatic morphological changes in Ras-transformed cells.
  • Microtubule dynamics, rather than actin, are critically involved in mediating these FTI-induced morphological alterations.
  • FTIs influence cell cycle progression, with potential synergistic effects with microtubule inhibitors.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...